TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive Only 10% Of Breast Cancer Patients May Benefit From Contralateral Mastectomy March 26, 2010
TCL Archive In Brief: NCI Claim “Major Finding” In Treatment Of Soft Tissue Sarcoma With Three Modalities; 93% Survival October 9, 1981
